Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of SLCO1B1 T521C on Statin-induced Myotoxicity: A Systematic Review and Meta-analysis

SLCO1B1 T521C가 스타틴에 의한 근육독성 발생에 미치는 영향: 체계적 문헌고찰 및 메타분석

  • Lee, Young Sook (College of Pharmacy, Keimyung University) ;
  • Chun, Pusoon (College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University)
  • 이영숙 (계명대학교 약학대학) ;
  • 천부순 (인제대학교 약학대학 인제약학연구소)
  • Received : 2018.08.23
  • Accepted : 2018.10.06
  • Published : 2018.12.29
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This study was performed to clarify the effect of SLCO1B1 T521C on statin-induced myotoxicity. Methods: The PubMed, Embase, Ovid, and Cochrane Library databases were searched for all published studies between database inception and April 2018. Using Review Manager 5, the pooled odds ratio (OR) and corresponding 95% confidence interval (CI) were determined to assess the effect of SLCO1B1 T521C on statin-induced myotoxicity by using different genetic models. Results: Eleven observational studies and one randomized controlled trial were included in the meta-analysis. The pooled analysis showed that the incidence of statin-induced myotoxicity was significantly associated with the SLCO1B1 521C variant allele. Among patients using statins, the incidence of myotoxicity was higher in those carrying the 521TC or 521CC variant than in those carrying the 521TT variant in the dominant model (TC + CC vs TT, OR: 1.57; 95% CI: 1.20, 2.05; p = 0.001). The 521TC genotype was associated with a higher risk of myotoxicity than the 521TT genotype (OR: 1.42; 95% CI: 1.09, 1.86; p = 0.009). Furthermore, the incidence of myotoxicity was higher in 521CC carriers than in 521TC carriers (OR: 1.40; 95% CI: 1.06, 1.83; p = 0.02) and noticeably higher in 521CC carriers than in 521TT carriers (OR: 2.26; 95% CI: 1.23, 4.17; p = 0.009). Conclusion: The identification of individuals with the SLCO1B1 521C variant allele prior to the initiation of statin therapy might be useful to predict the risk of toxicity development, determine the individual dose, and prevent myotoxicity.

Keywords

References

  1. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. https://doi.org/10.1016/S0140-6736(12)60367-5
  2. BIT Druginfo. Available from: https://www.druginfo.co.kr. Accessed 25 June, 2018.
  3. Drugs@FDA. Available from: https://www.accessdata.fda.gov/. Accessed 25 June, 2018.
  4. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3-11. https://doi.org/10.1016/j.phrs.2014.03.002
  5. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23(5):729-36. https://doi.org/10.1161/01.ATV.0000063385.12476.A7
  6. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007;93(8):1001-7. https://doi.org/10.1136/hrt.2006.088211
  7. Tousoulis D, Psarros C, Demosthenous M, et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 2014;63(23):2491-502. https://doi.org/10.1016/j.jacc.2014.01.054
  8. Stroes ES, Thompson P D, Corsini A. et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22. https://doi.org/10.1093/eurheartj/ehv043
  9. du Souich P, Roederer G, Dufour R. Myotoxicity of statins: mechanism of action 2017;175:1-16. https://doi.org/10.1016/j.pharmthera.2017.02.029
  10. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007;100(9):1400-3. https://doi.org/10.1016/j.amjcard.2007.06.030
  11. Choi HK, Won EK, Choung SY. Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats. Biomol Ther (Seoul) 2016;24(2):171-7. https://doi.org/10.4062/biomolther.2015.089
  12. Tomaszewski M, Stepien KM, Tomaszewska J, et al. Statin-induced myopathies. Pharmacol Rep 2011;63(4):859-66. https://doi.org/10.1016/S1734-1140(11)70601-6
  13. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med 2012;23(4):317-24. https://doi.org/10.1016/j.ejim.2012.01.004
  14. Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007;16(3):352-8. https://doi.org/10.1002/pds.1287
  15. El-Salem K, Ababneh B, Rudnicki S, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 2011;44(6):877-81. https://doi.org/10.1002/mus.22205
  16. Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics 2012;13(5):579-94. https://doi.org/10.2217/pgs.12.11
  17. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278(1):G156-64. https://doi.org/10.1152/ajpgi.2000.278.1.G156
  18. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007;8(7):787-802. https://doi.org/10.2217/14622416.8.7.787
  19. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63(1):157-81. https://doi.org/10.1124/pr.110.002857
  20. Hou Q, Li S, Li L, et al. Association between SLCO1B1 Gene T521C polymorphism and statin-related myopathy risk: A meta-analysis of case-control studies. Medicine (Baltimore) 2015;94(37):e1268 https://doi.org/10.1097/MD.0000000000001268
  21. Danik JS, Chasman DI, MacFadyen JG, et al. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J 2013;165(6):1008-14. https://doi.org/10.1016/j.ahj.2013.01.025
  22. Sessa M, Rafaniello C, Scavone C, et al. Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system? Expert Opin Drug Saf 2018;17(5):457-65. https://doi.org/10.1080/14740338.2018.1458837
  23. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72. https://doi.org/10.1016/S0735-1097(02)02030-2
  24. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292(11):1307-16. https://doi.org/10.1001/jama.292.11.1307
  25. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from http://konos.go.kr/konosis/common/bizlogic.jsp. Accessed June 1, 2018.
  26. Zheng JS, Hu XJ, Zhao YM, et al. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ 2013;346:f3706. https://doi.org/10.1136/bmj.f3706
  27. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Available from www.handbook.cochrane.org. Accessed June 1, 2018.
  28. Zhang BB, Xuan C, Deng KF, et al. Association between the MDR1 gene variant C3435T and risk of leukaemia: a meta-analysis. Eur J Cancer Care (Engl) 2013;22(5):617-25. https://doi.org/10.1111/ecc.12067
  29. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or $I^{2}$ index? Psychol Methods 2006;11(2):193-206. https://doi.org/10.1037/1082-989X.11.2.193
  30. Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320(7249):1574-7. https://doi.org/10.1136/bmj.320.7249.1574
  31. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54(17):1609-16. https://doi.org/10.1016/j.jacc.2009.04.053
  32. Linde R, Peng L, Desai M, et al. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol 2010;2(2):77-84. https://doi.org/10.4161/derm.2.2.13509
  33. Santos PC, Gagliardi AC, Miname MH, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68(3):273-9. https://doi.org/10.1007/s00228-011-1125-1
  34. Donnelly LA, Doney AS, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 2011;89(2):210-6. https://doi.org/10.1038/clpt.2010.255
  35. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statininduced myopathy-a genomewide study. N Engl J Med 2008;359:789-99. https://doi.org/10.1056/NEJMoa0801936
  36. Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011;21(5):280-8. https://doi.org/10.1097/FPC.0b013e328343dd7d
  37. Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12(3):233-7. https://doi.org/10.1038/tpj.2010.92
  38. Carr DF, O'Meara H, Jorgensen AL, et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther 2013;94(6):695-701. https://doi.org/10.1038/clpt.2013.161
  39. Mirosevic Skvrce N, Macolic Sarinic V, Simic I, et al. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics 2015;16(8):803-15. https://doi.org/10.2217/pgs.15.47
  40. Liu JE, Liu XY, Chen S, et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol 2017;73(11):1409-16. https://doi.org/10.1007/s00228-017-2318-z
  41. Bakar NS, Neely D, Avery P, et al. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. Clin Pharmacol Ther 2018;104(1):178-87. https://doi.org/10.1002/cpt.887
  42. Ferrari M, Guasti L, Maresca A, et al. Association between statininduced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol 2014;70(5):539-47. https://doi.org/10.1007/s00228-014-1661-6
  43. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16(12):873-9. https://doi.org/10.1097/01.fpc.0000230416.82349.90
  44. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013;127(1):96-103. https://doi.org/10.1161/CIRCULATIONAHA.112.136101
  45. Jiang J, Tang Q, Feng J, et al. Association between SLCO1B1 -521T > C and -388A > G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis. Springerplus 2016;5(1):1368. https://doi.org/10.1186/s40064-016-2912-z
  46. Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120(2):525-33. https://doi.org/10.1053/gast.2001.21176
  47. Zair ZM, Eloranta JJ, Stieger B, et al. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 2008;9(5):597-624. https://doi.org/10.2217/14622416.9.5.597
  48. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158(3):693-705. https://doi.org/10.1111/j.1476-5381.2009.00430.x
  49. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011;10(3):373-87. https://doi.org/10.1517/14740338.2011.540568
  50. Vildhede A, Karlgren M, Svedberg EK, et al. Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos 2014;42(7):1210-8. https://doi.org/10.1124/dmd.113.056309